Get the Stockscreener App
113.59
1.17%
1.31
After Hours:
113.20
-0.39
-0.34%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $113.59, with a volume of 9.30M.
It is up +1.17% in the last 24 hours and down -9.79% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$112.28
Open:
$111.74
24h Volume:
9.30M
Relative Volume:
1.09
Market Cap:
$197.52B
Revenue:
$44.33B
Net Income/Loss:
$6.48B
P/E Ratio:
30.67
EPS:
3.7033
Net Cash Flow:
$6.92B
1W Performance:
+4.98%
1M Performance:
-9.79%
6M Performance:
-13.53%
1Y Performance:
-13.58%
1-Day Range:
$111.38
$113.73
1-Week Range:
$107.91
$113.73
52-Week Range:
$105.27
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
113.59 | 195.24B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
363.70 | 138.08B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
101.08 | 130.02B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
73.47 | 110.11B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 44.71B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Drug of Abuse Testing Market Is Going to Boom |• Abbott - openPR.com
US Says Abbott Lied, Must Repay Funds Spent On Formula - Law360
Exact Sciences Faces Shareholder Lawsuits Over Abbott Merger - TipRanks
Abbott stock rises on AFib device data buzz as traders weigh FDA overhang - Bez Kabli
Abbott Laboratories price tries to correct main downward trendForecast today10-02-2026 - Economies.com
After a 15% Drop, Is Abbott Stock Set Up for a Comeback in 2026? - TIKR.com
Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica - GlobeNewswire Inc.
Wealthfront Advisers LLC Reduces Stock Position in Abbott Laboratories $ABT - MarketBeat
Johnson Investment Counsel Inc. Has $130.71 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott details Volt, TactiFlex data; Pulse Biosciences’ results shine - MedTech Dive
Assessing Abbott Laboratories (ABT) Valuation After New AFib Catheter And Pulsed Field Ablation Data - simplywall.st
Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating - Finviz
Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy - TechStock²
Analysts’ Top Healthcare Picks: Mettler-Toledo (MTD), Abbott Laboratories (ABT) - The Globe and Mail
Insider Stock Buying Reaches US$3.10m On Abbott Laboratories - Yahoo Finance
Top Abbott Insider Quietly Makes a Bold Million-Dollar Move - TipRanks
Abbott Labs CEO makes $2M bet as stock sinks - thestreet.com
Abbott Laboratories Announces Measurable Results From LATAM Diagnostic Market Development and Training Initiative Led by Claudia Marcela Riaño Caro - PRWeb
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
Abbott Laboratories (NYSE:ABT) Director Daniel Starks Purchases 10,000 Shares - MarketBeat
William Blair Maintains Abbott Laboratories(ABT.US) With Buy Rating - 富途牛牛
Abbott studies support pulsed field ablation, dual ablation catheters - MassDevice
Abbott Stock: 2026 Recovery Outlook After a 17% Decline - TIKR.com
Abbott (ABT) Showcases Promising AFib Therapy Advances at Boston Symposium - GuruFocus
Abbott reports positive results from study on its atrial fibrillation therapies - AlphaStreet News
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Abbott’s atrial fibrillation treatments show strong results in new studies By Investing.com - Investing.com India
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $135 - 富途牛牛
Abbott Labs director Starks buys shares worth $1.08 million By Investing.com - Investing.com Nigeria
Abbott Labs director Starks buys shares worth $1.08 million - Investing.com
Catheter trials show Abbott devices cut AFib episodes for most patients - Stock Titan
Aurdan Capital Management LLC Lowers Stake in Abbott Laboratories $ABT - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Lowers Position in Abbott Laboratories $ABT - MarketBeat
UK’s NICE recommends Abbott’s Cardiomems heart failure system - BioWorld MedTech
Abbott on track with dual sensor, FDA warns on FreeStyle Libre - Modern Healthcare News
BTIG Reaffirms Their Buy Rating on Abbott Laboratories (ABT) - The Globe and Mail
Bessemer Group Inc. Purchases 10,684 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Homestead Advisers Corp - MarketBeat
Abbott Laboratories $ABT Shares Bought by Savant Capital LLC - MarketBeat
US FDA says injuries from Abbott’s recalled glucose sensors reach 860 - WHTC
ABN AMRO Bank N.V. Makes New Investment in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories: How a 136-Year-Old Medtech Giant Is Re?Engineering the Future of Diagnostics an - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
US FDA says injuries from Abbott's recalled glucose sensors reach 860 - marketscreener.com
Abbott recalls glucose sensors after seven deaths linked to faulty readings - marketscreener.com
Abbott Laboratories (ABT) Faces FDA's Most Serious Recall Over G - GuruFocus
Abbott glucose monitor recall classified as most serious (ABT) - Seeking Alpha
Do Wall Street Analysts Like Abbott Laboratories Stock? - Yahoo Finance
FDA demands better response from Abbott over Libre inspection violations - Fierce Biotech
Hantz Financial Services Inc. Sells 29,746 Shares of Abbott Laboratories $ABT - MarketBeat
Envestnet Asset Management Inc. Sells 169,808 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbott Laboratories Stock (ABT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ford Robert B | CHAIRMAN AND CEO |
Jan 23 '26 |
Buy |
107.13 |
18,800 |
2,013,967 |
216,203 |
| Shroff Eric | Senior Vice President |
Nov 25 '25 |
Sale |
128.02 |
1,586 |
203,043 |
30,384 |
0.73%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):